<div id="readability-page-1">Syndax Pharmaceuticals (NASDAQ:SNDX) added ~21% in the premarket on Tuesday after the cancer drugmaker reported better-than-expected Q2 2025 financials, prompting Citi to issue a 90-day upside catalyst watch on the stock. The New York-based biotech posted ~$38.0M of revenue for the period, exceeding the Street forecasts by as much as $11.3M amid st...</div>

SNDX

<p>Syndax Pharmaceuticals (NASDAQ:SNDX) shares surged ~21% in premarket trading after reporting Q2 2025 financials that exceeded expectations, with ~$38.0M in revenue, surpassing forecasts by $11.3M. Strong sales from leukemia drug Revuforj ($28.6M) and graft-versus-host disease therapy Niktimvo ($36.2M) drove the results. Citi analyst Yigal Nochomovitz issued a 90-day upside catalyst watch, raising the price target from $46 to $51, citing potential for further stock gains as both treatments advance in the market.</p>

Syndax Pharma 在第二季度業績超預期後股價上漲；花旗銀行發佈了上行催化劑觀察